This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Busy Week for Six Biotech Stocks

BOSTON ( TheStreet) -- Three drug approval decisions and a cancer drug data presentation highlight a busy week ahead in biotech.

Traders will be eyeing Acura Pharmaceuticals (ACUR - Get Report) early Monday to see how the stock reacts following the U.S. approval of the company's tamper-resistant painkiller Oxecta on Friday night. Pfizer (PFE - Get Report), Acura's marketing partner, will sell Oxecta in the U.S.

Acura shares closed Friday's regular session down 5% to $3.87 but is sure to rebound and move higher when trading opens Monday. How much so likely depends on the data and language FDA allowed in the Oxecta label describing the drug's tamper-resistant qualities.

Pain Therapeutics (PTIE) is expecting an FDA approval decision on Thurs. June 23 for its own tamper-resistant opioid, Remoxy, which is also being developed in a partnership with Pfizer.

Remoxy was first submitted for FDA approval three years ago so Pain Therapeutics shareholders are hoping this week brings a positive end to what's been a long wait. Pain Therapeutics shares closed Friday at $8.64 -- watch Monday to see if investors move the stock higher on bullish sentiment stemming from the approval of Acura's Oxecta.

Curis (CRIS - Get Report) shares will be under a spotlight Monday on the release of data from a phase II study of vismodegib in basal cell carcinoma, a form of skin cancer.

The overall response rate in the study, assessed independently, showed vismodegib shrank tumors in 43% of patients with locally advanced basal cell carcinoma and 30% of patients with metastatic basal cell carcinoma. The median duration of response was 7.8 months, according to Curis. Patients in the phase II study had advanced basal cell carcinoma that was no longer responsive to any other therapy.

Roche is developing vismodegib under a partnership agreement with Curis and has already announced plans to seek U.S. approval later this year.

Switching back to FDA drug approvals this week, Fibrocell (FCSC.OB) awaits a June 22 decision on laViv, a personalized cell therapy for the treatment (smoothing out) of nasolabial fold wrinkles -- those are the skin folds that run from each side of the nose to the corners of the mouth.

What makes laViv different from Botox and the myriad of dermal fillers used commonly in cosmetic skin procedures today is its active ingredient -- a patient's own fibroblasts. These are a form of stem cell that matures into connective tissue fibers and help give skin strength and elasticity.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACUR $3.28 0.00%
BIIB $274.99 0.00%
CRIS $2.00 0.00%
PFE $32.71 0.00%
PTIE $2.42 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs